{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:24:59Z","timestamp":1774981499140,"version":"3.50.1"},"reference-count":23,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Envision Pharma Group","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche Group","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2023,12,31]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>We characterised the relationships between monitoring frequency, ranibizumab injection need and vision in patients receiving as-needed (pro re nata; PRN) ranibizumab for macular oedema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in this post-hoc analysis of SHORE and HORIZON.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients aged 18 years and older with macular oedema due to BRVO\/CRVO were included in this analysis. Injection frequency and best-corrected visual acuity (BCVA) were evaluated by PRN injection frequency in the PRN dosing phase (months (M) 7\u201315) of SHORE and through 12 months of HORIZON. Prespecified PRN re-treatment criteria for each trial were based on protocol-prespecified BCVA and optical coherence tomography outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After the initial 7\u2009monthly ranibizumab injections, patients in SHORE gained a mean of 18.3 letters from baseline. Patients randomised to PRN, on average, maintained these gains. However, some patients experienced additional mean gains, whereas others suffered losses (range 4.0 (95% CI 0.7 to 7.3) to \u22124.6 (95% CI \u221211.8 to 2.6) letters in patients who received 0 and 6\u20137 PRN injections, respectively). In BRAVO and CRUISE (lead-in trials), patients experienced mean gains from baseline to M6 (monthly dosing) of 19.3 and 15.0 letters, respectively, with gains maintained with PRN from M6 to M12. However, mean BCVA changes from baseline to M12 varied in HORIZON (range \u22120.4 (95% CI \u22122.5 to 1.6) to \u22123.6 (95% CI \u22126.2 to \u22121.0) letters in patients who received zero and six injections, respectively, during the preceding PRN phase of BRAVO and CRUISE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The BRVO\/CRVO population is heterogenous with a varied response to ranibizumab treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2022-323120","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T18:20:53Z","timestamp":1706638853000},"page":"1216-1225","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab"],"prefix":"10.1136","volume":"108","clinical-trial-number":[{"clinical-trial-number":"nct01277302","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00486018","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00485836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00379795","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-7570","authenticated-orcid":false,"given":"Robert B","family":"Bhisitkul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Blotner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Quezada-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenka","family":"Haskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2024082203451047000_108.9.1216.1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ophtha.2019.09.029","article-title":"Retinal Vein Occlusions Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"2024082203451047000_108.9.1216.2","unstructured":"Lucentis [package insert]. South San Francisco, CA: Genentech, Inc, 2018."},{"key":"2024082203451047000_108.9.1216.3","unstructured":"Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc, 2021."},{"key":"2024082203451047000_108.9.1216.4","unstructured":"Lucentis [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited, 2022."},{"key":"2024082203451047000_108.9.1216.5","unstructured":"Eylea [summary of product characteristics]. Leverkusen, Germany: Bayer AG, 2022."},{"key":"2024082203451047000_108.9.1216.6","unstructured":"Lucentis [product mongraph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc, 2015."},{"key":"2024082203451047000_108.9.1216.7","unstructured":"Eylea [product monograph]. Mississauga, Ontario, Canada: Bayer Inc, 2022."},{"key":"2024082203451047000_108.9.1216.8","unstructured":"Lucentis [Australian product information]. Macquarie Park, New South Wales, Australia: Novartis Pharmaceuticals Australia Pty Ltd, 2020."},{"key":"2024082203451047000_108.9.1216.9","unstructured":"Eylea [Australian product information]. Pymble, New South Wales, Australia: Bayer Australia Ltd, 2013."},{"key":"2024082203451047000_108.9.1216.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"2024082203451047000_108.9.1216.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.022"},{"key":"2024082203451047000_108.9.1216.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"2024082203451047000_108.9.1216.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"2024082203451047000_108.9.1216.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.005"},{"key":"2024082203451047000_108.9.1216.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.06.011"},{"key":"2024082203451047000_108.9.1216.16","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/OPTH.S209253","article-title":"Real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study","volume":"13","author":"Callizo","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"2024082203451047000_108.9.1216.17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2147\/OPTH.S100168","article-title":"Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion","volume":"10","author":"Sivaprasad","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"2024082203451047000_108.9.1216.18","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"key":"2024082203451047000_108.9.1216.19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2017.6843","article-title":"Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti\u2013vascular endothelial growth factor medications: secondary outcomes from the SCORE2 randomized clinical trial","volume":"136","author":"Scott","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2024082203451047000_108.9.1216.20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaophthalmol.2019.3947","article-title":"Month 24 outcomes after treatment initiation with anti\u2013vascular endothelial growth factor therapy for macular edema due to central retinal or hemiretinal vein occlusion: SCORE2 report 10: a secondary analysis of the SCORE2 randomized clinical trial","volume":"137","author":"Scott","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2024082203451047000_108.9.1216.21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.oret.2019.08.009","article-title":"Spectral-domain OCT predictors of visual outcomes after ranibizumab treatment for macular edema resulting from retinal vein occlusion","volume":"4","author":"Yiu","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"2024082203451047000_108.9.1216.22","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.10"},{"key":"2024082203451047000_108.9.1216.23","first-page":"361","article-title":"Ranibizumab: phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2022-323120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T10:59:05Z","timestamp":1724324345000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2022-323120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bjo-2022-323120"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2022-323120","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}